Aurealis Therapeutics receives Clinical Trial Application approval for AUP-16 Phase 1 DFU study
Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans to enroll the first patient to the phase […]
Aurealis Therapeutics announces 7.8MCHF financing to advance lead candidate AUP-16 for diabetic foot ulcers under new brand: Aurealis Therapeutics AG
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a […]
Aurealis Therapeutics submits Clinical Trial Application for AUP-16 Phase 1 DFU study
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application (CTA) to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate AUP1602-C to be studied in a first-in-human phase 1-2A clinical study as treatment of […]
Aurealis Therapeutics to strengthen its Board of Directors by appointing Iain Buchanan
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board members CSO and founder Mr. Thomas Wirth, senior life science executive, Mrs. Nora Kaarela, senior […]
Aurealis Therapeutics to present at the European Wound Management Association (EWMA) Congress 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company’s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at the European Wound Management Association (EWMA) Congress in Krakow, Poland […]
Aurealis Therapeutics to attend the Swiss Biotech Day 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company’s progress at the Swiss Biotech Day in Basel on May 3rd 2018. The Swiss Biotech Day has long become the standard annual get-together […]
Aurealis Therapeutics to present at the 11th Annual European Life Sciences CEO Forum & Exhibition
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on February 26-27th 2018. The presentation is scheduled for Monday, February […]
Aurealis Therapeutics to present at Swiss Nordic Bio 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018. The presentation is scheduled for: Time: Thursday, February 8th 2018 […]
